SKI-O-703

DRUG2 trials

Sponsors

Oscotec Inc.

Conditions

Immune ThrombocytopeniaRheumatoid Arthritis

Phase 2

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

CompletedNCT04056195

Oscotec Inc.Immune Thrombocytopenia

Start: 2019-10-11End: 2023-01-10Updated: 2024-07-10

A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

CompletedNCT04057118

Oscotec Inc.Rheumatoid Arthritis

Start: 2019-03-20End: 2020-10-13Updated: 2024-07-31